Готові списки джерел за темами / Sodium polystyrene sulphonate

Добірка наукової літератури з теми "Sodium polystyrene sulphonate"

Автор: Grafiati
Опубліковано: 18 травня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Sodium polystyrene sulphonate".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Sodium polystyrene sulphonate"

1

Harrison, Ian, and Jennifer J. W. Higgo. "The preparation of 125I-labelled sodium polystyrene sulphonate." Applied Radiation and Isotopes 45, no. 3 (March 1994): 345–51. http://dx.doi.org/10.1016/0969-8043(94)90049-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Dalvi, Anant G., Sridevi Allu, Massoma Niazi, and Gilda Diaz-Fuentes. "SODIUM POLYSTYRENE SULPHONATE (KAYEXALATE) ASPIRATION: AN INCIDENTAL NECROPSY FINDING." Chest 130, no. 4 (October 2006): 309S. http://dx.doi.org/10.1378/chest.130.4_meetingabstracts.309s-a.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Ghazouani, Anis, Sondes Boughammoura, and Jalel M'Halla. "Studies of Electrolytic Conductivity of Some Polyelectrolyte Solutions: Importance of the Dielectric Friction Effect at High Dilution." Journal of Chemistry 2013 (2013): 1–15. http://dx.doi.org/10.1155/2013/852752.

Повний текст джерела
Анотація:
We present a general description of conductivity behavior of highly charged strong polyelectrolytes in dilute aqueous solutions taking into account the translational dielectric friction on the moving polyions modeled as chains of charged spheres successively bounded and surrounded by solvent molecules. A general formal limiting expression of the equivalent conductivity of these polyelectrolytes is presented in order to distinguish between two concentration regimes and to evaluate the relative interdependence between the ionic condensation effect and the dielectric friction effect, in the range of very dilute solutions for which the stretched conformation is favored. This approach is illustrated by the limiting behaviors of three polyelectrolytes (sodium heparinate, sodium chondroitin sulfate, and sodium polystyrene sulphonate) characterized by different chain lengths and by different discontinuous charge distributions.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Gardiner, Geoffrey W. "Kayexalate (Sodium Polystyrene Sulphonate) in Sorbitol Associated with Intestinal Necrosis in Uremic Patients." Canadian Journal of Gastroenterology 11, no. 7 (1997): 573–77. http://dx.doi.org/10.1155/1997/370814.

Повний текст джерела
Анотація:
BACKGROUND:Kayexalate (sodium polystyrene sulphonate) in sorbitol is commonly used to treat hyperkalemia in patients with renal insufficiency. Isolated case reports and one recent large series have documented intestinal necrosis following administration of kayexalate in sorbitol.METHODS:Two patients with luminal kayexalate crystals associated with intestinal pathology were first identified in the pathology department, and clinicopathological correlation was carried out.RESULTS:Both patients were seriously ill, had prior cardiac surgery and were in renal failure (uremic). Examination of autopsy and colonic resection showed luminal kayexalate crystals associated with underlying mucosal necrosis, submucosal edema and transmural inflammation.CONCLUSION:Although occurring in complex clinical settings, the pathological findings provide additional evidence that kayexalate in sorbitol may be associated with intestinal necrosis and inflammation in uremic patients and that this may be a clinically and pathologically under-recognized iatrogenic bowel injury.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Bianchi, Stefano, and Giuseppe Regolisti. "Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia." Nephrology Dialysis Transplantation 34, Supplement_3 (December 1, 2019): iii51—iii61. http://dx.doi.org/10.1093/ndt/gfz213.

Повний текст джерела
Анотація:
Abstract Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with advanced stages of chronic kidney disease (CKD), is a potentially life-threatening clinical condition due to an increased risk of fatal arrhythmias, and strongly impacts the quality of life and prognosis of CKD patients. Moreover, while renin–angiotensin–aldosterone system inhibitors (RAASIs) represent the most cardio-nephro-protective drugs used in clinical practice, the treatment with these drugs per se increases serum potassium (sK) values, particularly when heart failure and diabetes mellitus coexist. In fact, the onset or recurrence of HK is frequently associated with not starting, down-titrating or withdrawing RAASIs, and is an indication to begin renal replacement treatment in end-stage renal disease. Current strategies aimed at preventing and treating chronic HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials. Indeed, dietary potassium restriction, the use of sodium bicarbonate or diuretics, the withdrawal or down-titration of RAASIs, or the administration of old potassium binders, namely sodium polystyrene sulphonate and calcium polystyrene sulphonate, have limited efficacy and are poorly tolerated; therefore, these strategies are not suitable for long-term control of sK. As such, there is an important unmet need for novel therapeutic options for the chronic management of patients at risk for HK. The development of new potassium binders may change the treatment landscape in the near future. This review summarizes the current evidence on the treatment of chronic HK in cardio-renal patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Sportelli, Maria C., Diana Hötger, Rosaria A. Picca, Kyriaki Manoli, Christine Kranz, Boris Mizaikoff, Luisa Torsi, and Nicola Cioffi. "Electrosynthesized Polystyrene Sulphonate-Capped Zinc Oxide Nanoparticles as Electrode Modifiers for Sensing Devices." MRS Proceedings 1675 (2014): 15–20. http://dx.doi.org/10.1557/opl.2014.847.

Повний текст джерела
Анотація:
ABSTRACTZnO nanoparticles were prepared by a green electrochemical synthesis method applying low current densities followed by a thermal treatment. Sodium polystyrene sulphonate (PSS) was used as stabilizer in the electrolytic aqueous medium due to its biocompatibility and stability. The as-prepared nanocolloids were then annealed to improve their stability, and then converted via hydroxide species into stoichiometric oxide. Different calcination temperatures were studied. ZnO@PSS nanomaterials were deposited onto SiO2/Si substrates, in part in combination with an organic semiconductor layer to evaluate their influence on organic field effect transistors (OFETs). All nanomaterials and composite layers were characterized by morphological and spectroscopic techniques. Promising results regarding the use of ZnO@PSS in OFETs could be demonstrated.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Filippi, Luca, Alessandra Cecchi, Carlo Dani, Giovanna Bertini, Marco Pezzati, and Firmino F. Rubaltelli. "Hypernatraemia induced by sodium polystyrene sulphonate (KayexalateR) in two extremely low birth weight newborns." Pediatric Anesthesia 14, no. 3 (March 2004): 271–75. http://dx.doi.org/10.1046/j.1460-9592.2003.01210.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Avernier, B. H., J. Vliegen, J. Mullens, and C. Van Poucke. "Study of the Desorption of Gelatin on Silver Bromide by Means of Sodium Polystyrene Sulphonate." Journal of Photographic Science 34, no. 4 (July 1986): 125–32. http://dx.doi.org/10.1080/00223638.1986.11738411.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Abad, Concepción, Lorenzo Braco, Vicente Soria, Rosa García, and Agustín Campos. "Solution properties of polyelectrolytes. I. Exclusion chromatography of sodium polystyrene sulphonate in salt-free water as eluent." British Polymer Journal 19, no. 6 (November 1987): 489–500. http://dx.doi.org/10.1002/pi.4980190601.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Laureati, Paola, Yang Xu, Marco Trevisan, Lovisa Schalin, Illaria Mariani, Rino Bellocco, Manish M. Sood, et al. "Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study." Nephrology Dialysis Transplantation 35, no. 9 (August 4, 2019): 1518–26. http://dx.doi.org/10.1093/ndt/gfz150.

Повний текст джерела
Анотація:
Abstract Background Despite long-standing clinical use of sodium polystyrene sulphonate (SPS) for hyperkalaemia management in chronic kidney disease (CKD), its safety profile remains poorly investigated. Methods We undertook an observational analysis of nephrology-referred adults with incident CKD Stage 4+ in Sweden during 2006–16 and with no previous SPS use. We studied patterns of use and adverse events associated to SPS initiation during follow-up. Patterns of SPS use were defined by chronicity of treatment and by prescribed dose. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) associated with SPS initiation (time-varying exposure) for the risk of severe (intestinal ischaemia, thrombosis or ulceration/perforation) and minor (de novo dispensation of laxatives or anti-diarrheal drugs) gastrointestinal (GI) events. Results Of 19 530 SPS-naïve patients with CKD, 3690 initiated SPS during follow-up. A total of 59% took SPS chronically, with an average of three dispensations/year. The majority (85%) were prescribed lower dosages than specified on the product label. During follow-up, 202 severe and 1149 minor GI events were recorded. SPS initiation was associated with a higher incidence of severe adverse events [adjusted HR 1.25 95% CI 1.05–1.49)], particularly in those receiving per label doses [1.54 (1.09–2.17)] and mainly attributed to ulcers and perforations. SPS initiation was also associated with higher incidence of minor GI events [adjusted HR 1.11 (95% CI 1.03–1.19)], regardless of dose, and mainly accounted for by de novo dispensation of laxatives. Conclusions Initiation of SPS in patients with advanced CKD is associated with a higher risk of severe GI complications as well as the initiation of GI-related medications, particularly when prescribed at per label doses.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Sodium polystyrene sulphonate"

1

Obey, T. M. "The configuration of sodium poly(styrene sulphonate) at polystyrene/solution interfaces." Thesis, University of Bristol, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.376486.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

De, Ranjit. "Solution properties of sodium polystyrene sulphonate in 2-ethoxyethanol-water mixed solvent media." Thesis, University of North Bengal, 2011. http://hdl.handle.net/123456789/1435.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Sodium polystyrene sulphonate"

1

"Sodium polystyrene sulphonate." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1601.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Sodium polystyrene sulphonate" для конкретних типів джерел:
Статті в журналах
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії